Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Zai Lab Ltd (ZLAB)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/07/2023 |
8-K
| Quarterly results |
| 07/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/30/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/09/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
8-K
| Quarterly results |
| 01/09/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/05/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 11/09/2022 |
8-K
| Quarterly results |
| 10/28/2022 |
8-K
| Quarterly results |
| 09/27/2022 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte... |
| 08/09/2022 |
8-K
| Quarterly results |
| 08/03/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/22/2022 |
8-K
| Quarterly results |
| 05/31/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 04/21/2022 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Zai Lab Announces Engagement of KPMG LLP, a U.S. Auditor, as the Company's Independent Registered Public Accounting Firm • Zai Lab's engagement of an audit firm located in the United States is expected to facilitate the Company's continued listing on Nasdaq because KPMG is subject to inspection by the PCAOB. SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., April 21, 2022 — Zai Lab Limited , a patient-focused, innovative, commercial-stage, global biopharmaceutical company, announced today that the Audit Committee of its Board of Directors has approved the engagement of KPMG as the Company's independent registered public accounting firm. KPMG will be engaged to audit the annual consolidated financial statements of Zai Lab and its subsidiaries filed with the U.S. Securities and Exchange Commiss..." |
|
| 04/01/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/28/2022 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 03/15/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Zai Lab Announces the Appointment of Josh Smiley as Chief Operating Officer SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass. March 15, 2022 —Zai Lab Limited , a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Josh Smiley as its Chief Operating Officer . Mr. Smiley brings over 26 years of experience working within the biopharmaceutical industry, including experience leading finance, corporate strategy, business development, venture capital and the Global Business Services operations at Eli Lilly and Co . “We are very pleased we will be able to welcome Josh at this exciting time, when we have so many potential breakthrough therapies in our pipeline,” said Dr. Samantha Du, CEO and Chair of the Board of Zai Lab. “Josh's extensive..." |
|
| 03/01/2022 |
8-K
| Quarterly results |
| 01/06/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"FORM 8-K",
"Zai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPA SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., January 6, 2022 - Zai Lab Limited , a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the China National Medical Products Administration has accepted the New Drug Application for margetuximab, an investigational, Fc-engineered monoclonal antibody that targets HER2. The margetuximab NDA is for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease, in combination with chemotherapy. “We are pleased to have NMPA's acceptance of our ND..." |
|
| 12/22/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/16/2021 |
8-K
| Quarterly results |
| 12/03/2021 |
8-K
| Quarterly results |
| 11/22/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"FORM 8-K",
"Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., November 22, 2021 — Zai Lab Limited , a patient-focused, innovative, commercial-stage, global biopharmaceutical company, announced today that it has appointed Richard Gaynor, M.D., to its Board of Directors. Dr. Gaynor will also serve as Chair of the Research and Development Committee. Dr. Gaynor is the President and Chief of Research and Development of BioNTech US. Prior to this, he was President, Research and Development, at Neon Therapeutics, beginning in 2016. Previously, Dr. Gaynor spent 15 years in senior roles at Lilly Oncology, including as Senior Vice President, Clinical Development and Medical Affairs. He chaired the Lilly Oncology Research and Development Committee and h..." |
|
| 11/09/2021 |
8-K
| Quarterly results |
| 11/05/2021 |
8-K
| Other Events Interactive Data |
| 10/20/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 10/19/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 10/18/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"FORM 8-K",
"Zai Lab Appoints Scott Morrison to its Board of Directors SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, MA, October 18, 2021 — Zai Lab Limited , a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it has appointed Scott Morrison to its Board of Directors. Mr. Morrison will also serve as a member of the Audit Committee. Mr. Morrison has served public and private companies in the life sciences industry since 1980. He was a Partner with Ernst & Young LLP from 1996 to 2015, serving as its U.S. Life Sciences Leader from 2002 to 2015. During his tenure at EY, he worked on hundreds of public and private financings, M&A transactions, and corporate collaborations. Mr. Morrison retired from EY in December 2015 and now serves on the boards and chairs the ..." |
|
| 08/09/2021 |
8-K
| Quarterly results |
| 06/24/2021 |
8-K
| Quarterly results |
| 06/16/2021 |
8-K
| Quarterly results |
| 06/01/2021 |
8-K
| Quarterly results |
|
|
|